Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Chemoradiotherapy in Stage IIIB NSCLC
NCT01059188Phase 2Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- May 2010
- Primary completion
- Dec 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in non-small cell lung cancer (NSCLC), sponsored by Swiss Group for Clinical Cancer Research. Started May 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01059188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01059188.